The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Two central nervous system disorder biotechs laid off employees recently. New York gene therapy startup Apertura and Boston ...

The FDA on Friday approved Astellas’ treatment for a type of gastric cancer, marketed as Vyloy (zolbetuximab). The approval ...

The European Medicines Agency’s human medicines committee again decided not to recommend the renewal of the conditional ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after ...

CVS Health is parting ways with CEO Karen Lynch as the pharmacy giant continues to struggle with problems in its insurance ...

Supernus Pharmaceuticals' mTORC1 activator has cleared a small trial in patients with major depressive disorder, potentially ...

Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, ...

Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...

Amicus Therapeutics resolved a patent dispute with Teva on Thursday, allowing Teva to launch a generic version of its Fabry ...

Amylyx is trying to move forward with its effort to turn its former ALS drug into a treatment for other conditions, and data ...